Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63.

Article  PubMed  Google Scholar 

Jokhadze N, Das A, Dizon DS. Global cancer statistics: a healthy population relies on population health. CA Cancer J Clin. 2024;74(3):224–6.

Article  PubMed  Google Scholar 

Harbeck N, Gnant M. Breast cancer. Lancet. 2017;389(10074):1134–50.

Article  PubMed  Google Scholar 

Burstein HJ et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021;32(10):1216–35.

Jiang X, et al. The role of microenvironment in tumor angiogenesis. J Exp Clin Cancer Res. 2020;39(1):204.

Article  PubMed  PubMed Central  Google Scholar 

Li YL, Hung WC. Reprogramming of sentinel lymph node microenvironment during tumor metastasis. J Biomed Sci. 2022;29(1):84.

Article  PubMed  PubMed Central  Google Scholar 

Nathanson SD, et al. Breast cancer metastasis through the lympho-vascular system. Clin Exp Metastasis. 2018;35(5–6):443–54.

Article  PubMed  Google Scholar 

Liang P, et al. Monotherapy and combination therapy using anti-angiogenic nanoagents to fight cancer. Adv Mater. 2021;33(15): e2005155.

Article  PubMed  Google Scholar 

Liu ZL, et al. Angiogenic signaling pathways and anti-angiogenic therapy for cancer. Signal Transduct Target Ther. 2023;8(1):198.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bao W, Li Z. Efficacy and safety of neoadjuvant chemotherapy containing anti-angiogenic drugs, immunotherapy, or PARP inhibitors for ovarian cancer. Crit Rev Oncol Hematol. 2024;194: 104238.

Article  PubMed  Google Scholar 

Lee WS, et al. Combination of anti-angiogenic therapy and immune checkpoint blockade normalizes vascular-immune crosstalk to potentiate cancer immunity. Exp Mol Med. 2020;52(9):1475–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Song Y, et al. Anti-angiogenic agents in combination with immune checkpoint inhibitors: a promising strategy for cancer treatment. Front Immunol. 2020;11:1956.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yamamoto Y, et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vasc Cell. 2014;6:18.

Article  PubMed  PubMed Central  Google Scholar 

Tohyama O, et al. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res. 2014;2014: 638747.

Article  PubMed  PubMed Central  Google Scholar 

Shiri P, et al. A patent review on efficient strategies for the total synthesis of pazopanib, regorafenib and lenvatinib as novel anti-angiogenesis receptor tyrosine kinase inhibitors for cancer therapy. Mol Divers. 2022;26(5):2981–3002.

Article  CAS  PubMed  Google Scholar 

Eisai Inc. Lenvima (lenvatinib) capsules, for oral use: US prescribing information. 2024 [cited 2024 2–24]. Available from: http://www.fda.gov.

Wirth LJ, et al. Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid cancer: treatment optimization for maximum clinical benefit. Oncologist. 2022;27(7):565–72.

Article  PubMed  PubMed Central  Google Scholar 

Motzer RJ, et al. Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trial. Lancet Oncol. 2015;16(15):1473–82.

Article  CAS  PubMed  Google Scholar 

Okamoto K, et al. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett. 2013;340(1):97–103.

Article  CAS  PubMed  Google Scholar 

Krishnapriya S, et al. Microvessel density (MVD) in locally advanced breast cancer. Asian Pac J Cancer Prev. 2019;20(5):1537–45.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tsutsui S, et al. The Akt expression correlates with the VEGF-A and -C expression as well as the microvessel and lymphatic vessel density in breast cancer. Oncol Rep. 2010;23(3):621–30.

Article  PubMed  Google Scholar 

Melincovici CS, et al. Vascular endothelial growth factor (VEGF)—key factor in normal and pathological angiogenesis. Rom J Morphol Embryol. 2018;59(2):455–67.

PubMed  Google Scholar 

Kim H, Kataru RP, Koh GY. Inflammation-associated lymphangiogenesis: a double-edged sword? J Clin Invest. 2014;124(3):936–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rinderknecht M, et al. Phage-derived fully human monoclonal antibody fragments to human vascular endothelial growth factor-C block its interaction with VEGF receptor-2 and 3. PLoS ONE. 2010;5(8): e11941.

Article  PubMed  PubMed Central  Google Scholar 

Patel SA, et al. Molecular mechanisms and future implications of VEGF/VEGFR in cancer therapy. Clin Cancer Res. 2023;29(1):30–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ma Q, Dieterich LC, Detmar M. Multiple roles of lymphatic vessels in tumor progression. Curr Opin Immunol. 2018;53:7–12.

Article  CAS  PubMed  Google Scholar 

Ribatti D, et al. Angiogenesis and antiangiogenesis in triple-negative breast cancer. Transl Oncol. 2016;9(5):453–7.

Article  PubMed  PubMed Central  Google Scholar 

Katoh M, Nakagama H. FGF receptors: cancer biology and therapeutics. Med Res Rev. 2014;34(2):280–300.

Article  CAS  PubMed  Google Scholar 

Zhang J, Li Y. Therapeutic uses of FGFs. Semin Cell Dev Biol. 2016;53:144–54.

Article  CAS  PubMed  Google Scholar 

Garcia-Lezana T, Lopez-Canovas JL, Villanueva A. Signaling pathways in hepatocellular carcinoma. Adv Cancer Res. 2021;149:63–101.

Article  CAS  PubMed  Google Scholar 

Yang L, et al. FGF/FGFR signaling: from lung development to respiratory diseases. Cytokine Growth Factor Rev. 2021;62:94–104.

Article  CAS  PubMed  Google Scholar 

Liu G, et al. Inhibition of FGF-FGFR and VEGF-VEGFR signalling in cancer treatment. Cell Prolif. 2021;54(4): e13009.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Helsten T, et al. The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing. Clin Cancer Res. 2016;22(1):259–67.

Article  CAS  PubMed  Google Scholar 

Formisano L, et al. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. Nat Commun. 2019;10(1):1373.

Article